FdaApplication
NDA 211230
Identifiers
- fda_app_no: NDA211230
Properties
| Property | Value |
|---|---|
| applicant_name | AXSOME MALTA LTD |
| application_type | NDA |
| approval_date | 2019-06-17 |
Revenue by product
SUNOSI
| Period | Revenue |
|---|---|
| Q2 2026 | $35.8M |
| Q1 2026 | $33.9M |
| Q3 2025 | $32.8M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SUNOSI | SOLRIAMFETOL HYDROCHLORIDE | EQ 75MG BASE | TABLET;ORAL |
| SUNOSI | SOLRIAMFETOL HYDROCHLORIDE | EQ 150MG BASE | TABLET;ORAL |
2 products